- Corporate Officers - S
- Slansky Richard B
Insider Trading History of Slansky Richard B
The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) by Slansky Richard B since 2010.
The trader's CIK number is 1224981.
At the time of the last reporting, Slansky Richard B was the Chief Financial Officer of Oncosec Medical Inc. (stock ticker symbol ONCS).
Also see all insider trading activities at Oncosec Medical Inc.
Note that in the past
SLANSKY RICHARD B also reported insider trading activities as an insider of the following companies:
Yearly summary of insider trading at Digirad Corp (DRAD) by Slansky Richard B
| | Insider Buying | Insider Sales | Option Exercises |
|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
|---|
| 2012 | DRAD | 0 | $0 | 0 | $0 | 8,418 | $0 |
| 2011 | DRAD | 0 | $0 | 0 | $0 | 8,945 | $0 |
| 2010 | DRAD | 0 | $0 | 0 | $0 | 3,415 | $0 |
Yearly summary of insider trading at Oncosec Medical Inc (ONCS) by Slansky Richard B
| | Insider Buying | Insider Sales | Option Exercises |
|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
|---|
| 2018 | ONCS | 0 | $0 | 84,984 | $118,460 | 200,000 | $0 |
| 2015 | ONCS | 150,000 | $918,000 | 0 | $0 | 0 | $0 |
Yearly summary of insider trading at Genmark Diagnostics, Inc. (GNMK) by Slansky Richard B
| | Insider Buying | Insider Sales | Option Exercises |
|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
|---|
| 2014 | GNMK | 0 | $0 | 4,820 | $52,058 | 0 | $0 |
| 2013 | GNMK | 0 | $0 | 660 | $7,735 | 0 | $0 |
| 2012 | GNMK | 25,000 | $105,000 | 0 | $0 | 0 | $0 |
Insider trading activities at 3 companies by Slansky Richard B:
1. Digirad Corp (DRAD)
2. Oncosec Medical Inc (ONCS)
3. Genmark Diagnostics, Inc. (GNMK)
Table 1. Insider trading of Digirad Corp (DRAD) by Slansky Richard B
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|
| 2012-04-10 | DRAD | Option Ex | 2,732 | .00 | 0 |
| 2012-04-10 | DRAD | Option Ex | 2,732 | .00 | 0 |
| 2012-01-17 | DRAD | Option Ex | 2,954 | .00 | 0 |
| 2011-10-11 | DRAD | Option Ex | 2,550 | .00 | 0 |
| 2011-07-14 | DRAD | Option Ex | 2,455 | .00 | 0 |
| 2011-04-25 | DRAD | Option Ex | 1,102 | .00 | 0 |
| 2011-01-18 | DRAD | Option Ex | 2,838 | .00 | 0 |
| 2010-10-11 | DRAD | Option Ex | 1,095 | .00 | 0 |
| 2010-08-09 | DRAD | Option Ex | 1,255 | .00 | 0 |
| 2010-06-25 | DRAD | Option Ex | 1,065 | .00 | 0 |
Table 2. Insider trading of Oncosec Medical Inc (ONCS) by Slansky Richard B
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|
| 2018-06-21 | ONCS | Sale | 4,944 | 1.40 | 6,926 |
| 2018-06-18 | ONCS | Sale | 12,613 | 1.39 | 17,481 |
| 2018-06-20 | ONCS | Sale | 24,906 | 1.42 | 35,416 |
| 2018-07-05 | ONCS | Sale | 6,725 | 1.31 | 8,823 |
| 2018-06-29 | ONCS | Sale | 2,420 | 1.38 | 3,339 |
| 2018-06-28 | ONCS | Sale | 3,532 | 1.40 | 4,948 |
| 2018-06-27 | ONCS | Sale | 7,832 | 1.37 | 10,761 |
| 2018-06-15 | ONCS | Option Ex | 200,000 | .00 | 0 |
| 2018-06-26 | ONCS | Sale | 10,673 | 1.40 | 14,920 |
| 2018-06-25 | ONCS | Sale | 458 | 1.41 | 643 |
| 2018-06-22 | ONCS | Sale | 6,710 | 1.42 | 9,514 |
| 2018-06-19 | ONCS | Sale | 4,171 | 1.36 | 5,689 |
| 2015-07-06 | ONCS | Buy | 150,000 | 6.12 | 918,000 |
Table 3. Insider trading of Genmark Diagnostics, Inc. (GNMK) by Slansky Richard B
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|
| 2014-05-08 | GNMK | Sale | 2,302 | 9.26 | 21,318 |
| 2014-03-11 | GNMK | Sale | 1,680 | 12.17 | 20,438 |
| 2014-02-07 | GNMK | Sale | 838 | 12.29 | 10,302 |
| 2013-11-06 | GNMK | Sale | 660 | 11.72 | 7,735 |
| 2012-06-26 | GNMK | Buy | 25,000 | 4.20 | 105,000 |
Insider trading activities including stock purchases, stock sales, and option exercises
listed in the above table cannot be completely guaranteed as to their accuracy.
For more information regarding the trades made by Slansky Richard B
(Chief Financial Officer of Oncosec Medical Inc at the time of this reporting) see
the Securities and Exchange Commission (SEC) website.